Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viatris (VTRS) and Beam Therapeutics (BEAM).

Viatris (VTRS)

Barclays analyst Balaji Prasad maintained a Buy rating on Viatris on May 11 and set a price target of $21.00. The company’s shares closed last Wednesday at $15.72.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 8.0% and a 52.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Amneal Pharmaceuticals.

Viatris has an analyst consensus of Moderate Buy, with a price target consensus of $18.29, a 20.3% upside from current levels. In a report issued on May 10, RBC Capital also maintained a Buy rating on the stock with a $23.00 price target.

See today’s analyst top recommended stocks >>

Beam Therapeutics (BEAM)

In a report issued on May 11, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics, with a price target of $68.00. The company’s shares closed last Wednesday at $66.88.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 18.3% and a 49.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Crispr Therapeutics AG, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Beam Therapeutics is a Moderate Buy with an average price target of $105.00, implying a 63.4% upside from current levels. In a report issued on May 3, RBC Capital also initiated coverage with a Hold rating on the stock with a $85.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.



Source link